6-K - GRFS - Equibles

UNITED STATESSECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934

For the month September 2022

(Commission File No. 001-35193)

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

Yes ¨ No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

Yes ¨ No x

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- . .

Grifols, S.A.

TABLE OF CONTENTS

Item		Sequential Page Number
1.	Other Relevant Information, dated September<br> 25, 2022	3
Grifols, S.A.<br><br><br><br><br>Avinguda de la Generalitat 152<br>-<br>158<br><br><br>08174 Sant Cugat del Vallès<br><br><br>Barcelona<br>-<br><br>ESPAÑA<br><br><br><br><br>Tel. [34]<br>935 710 500<br><br><br>Fax [34] 935 710 267<br><br><br><br><br>www.grifols.com<br><br><br><br><br>P<br>ursuant<br><br>to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved<br>by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the<br>following<br>:<br><br><br><br>OTHER RELEVANT INFORMATION<br><br><br>In<br>the<br>cont<br>ext of<br>considerable<br>g<br>eopolitical uncertainty and market volatility<br>, the Board of Directors of<br>Grifols, S.A<br><br>communicates the following:<br><br><br>-<br><br>Grifols advance<br>s<br><br>firmly in the execution of a strategic growth plan which continues to create<br>sustainable value for all<br>its shareholders.<br>The company’s fundamentals<br><br>remain<br>solid and robust<br>..<br><br><br>-<br><br>The development of key Biotest innovation projects continues advancing and<br>,<br><br>assuming<br>the<br><br>two<br>new protein products<br><br>IgM and fibrinogen<br><br>receive regulatory approval and are<br>fully<br>rolled out into<br>the market,<br>these products are<br>expected to<br><br>contribute significantly to<br>Grifols’<br>operating profit.<br>These projects complement Grifols’ current<br>innovation<br>projects<br><br>and<br>contribute to the company’s<br><br>soli<br>d<br>product development<br>pipeline<br>..<br><br><br>-<br><br>The<br>volume of<br><br>plasma<br>collection<br>has<br>rebounded<br><br>from pandemic lows<br>.. S<br>ince May<br>2022<br>, monthly<br>plasma<br><br>collection volume<br>s<br><br>have been<br><br>exceeding the average monthly collection volume in<br>2019<br>..<br><br><br>The<br><br>company is<br>also<br>actively working<br>on<br>operating<br>cost reductions<br>,<br><br>as well as<br>continuous<br>improvement<br>in<br>operational efficiencies<br><br>while re<br>building<br>inventory<br>..<br><br>Increased plasma collection<br>has in turn driven r<br>evenue growth; the company forecasts revenues for the second half of 2022 to<br>be<br>up by a double digit percentage amount compared to the second half of 2021.<br><br><br>-<br><br>The strategic agreement to<br>increase<br><br>self<br>-<br>sufficie<br>ncy in Canada<br><br>strengthens<br><br>Grifols’ positioning as<br>partner<br>of choice<br>in a pioneering public<br>-<br>private collaboration model in the industry<br>, which together<br>with that of Egypt, could be replicated in other countries.<br><br><br>-<br><br>The re<br>organization<br><br>of the company<br> ’s<br>organizational structure and<br>operational processes<br>,<br><br>to<br>accelerate greater agility and focus on the business units,<br>has already been implemented.<br><br><br>-<br><br>At the same time,<br>Grifols continues<br>to<br>attract<br><br>highly qualified<br>talent<br>,<br>with<br>two new execut<br>ives with<br>recognized international careers<br>expected to<br><br>join<br>the company<br>to manage the Biopharma and<br>Plasma<br>Procurement<br>business units.<br><br>Further detail will be provided shortly<br>..<br><br><br>-<br><br>We reiterate<br>this Board’s<br>commitment<br>to reduce debt levels<br>.. The<br>B<br>oard is evaluating several<br>strategic alternatives to achieve that goal<br>while also<br><br>improv<br>ing<br><br>the company’s<br>cash flow profile<br>..<br>The<br>B<br>oard also notes that the company had cash and unrestricted revolver borrowing capacity<br>totaling<br><br>over EUR<br><br>1.3<br><br>billion as of August 31, 2022.<br>In<br>all its<br><br>endeavors, the<br>B<br>oard is keenly focused<br>on increasing<br><br>value for all shareholders.
---
-<br><br>Grifols plans to<br><br>continue<br>to enhance<br>the frequency and effectiveness of Grifols’<br>communications.<br><br>We would like<br>also<br>to announce th<br>at<br>commencing with the first quarter of<br><br>2023, Grifols will<br>publish<br><br>quarterly earnings reports.<br><br><br><br><br><br>In Barcelona<br>,<br><br>on<br>September 25,<br><br>2022<br><br><br><br><br>President<br><br>of<br><br>the Board of Directors<br><br><br><br>Lead Independent Director<br><br>Víctor Grífols Roura<br><br><br><br><br><br>Carina<br>Szpilka<br><br><br><br><br><br><br><br><br><br><br>Legal<br>Disclaimer.<br><br>This communication contains forward<br>-<br>looking information and statements about<br>Grifols based on current assumptions and forecasts made by Grifols<br><br>management, including statements<br>regarding plans, objectives and expectations with respect to products, operating efficiencies, debt<br>levels,<br>strategy and<br>management<br>, and statements regarding future performance. Forward<br>-<br>looking<br>statements are statements th<br>at are not historical facts and are<br>generally identified by the word<br> “expected” and similar expressions.<br><br>Although Grifols believes that the expectations reflected in such forward<br>-<br>looking statements are<br>reasonable, various known and unknown risks, uncertain<br>ties<br><br>and other factors could lead to material<br>differences between the actual future results, financial situation, development or performance of the<br>company and/or its products, and the expectations set forth in this communication.<br><br>These factors<br>include<br><br>tho<br>se discussed in our public reports filed with the Comision Nacional del Mercado<br>de Valores and the Securities and Exchange Commission, which are accessible to the public. The<br>company assumes no liability<br><br>whatsoever to update these forward<br>-<br>looking statement<br>s or conform them<br>to future events of developments.<br>Forward<br>-<br>looking statements are not guarantees of future<br>performance.
---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Grifols, S.A.
By:	/s/<br> David I. Bell
	Name:	David I. Bell
	Title:	Authorized Signatory

Date: September 26, 2022